{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=12",
    "query": {
      "intervention": "Part 1",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 6229,
    "total_pages": 623,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T10:38:18.216Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04725188",
      "title": "Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab/Vibostolimab coformulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 255,
      "start_date": "2021-04-20",
      "completion_date": "2024-10-17",
      "has_results": true,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Hattiesburg",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04725188"
    },
    {
      "nct_id": "NCT07639827",
      "title": "A Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Wellness",
        "Self Compassion",
        "Burnout",
        "Anxiety",
        "Depression"
      ],
      "interventions": [
        {
          "name": "App-based bundled mental fitness intervention",
          "type": "OTHER"
        },
        {
          "name": "App-based wellness module collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-08",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07639827"
    },
    {
      "nct_id": "NCT01884727",
      "title": "Effect of ASEA on Energy Expenditure and Fat Oxidation in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Salt Water",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "ASEA water",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 65 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2012-11",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 1,
      "location_summary": "Kannapolis, North Carolina",
      "locations": [
        {
          "city": "Kannapolis",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01884727"
    },
    {
      "nct_id": "NCT07680686",
      "title": "Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Ubrogepant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2026-07-14",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07680686"
    },
    {
      "nct_id": "NCT01817686",
      "title": "Study of Default Options in Advance Directives",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COPD",
        "Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy",
        "Idiopathic Pulmonary Fibrosis",
        "Other Interstitial Lung Disease Without Curative Therapy",
        "Congestive Heart Failure",
        "NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year",
        "Malignancy",
        "Any Stage 3B or 4 Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Comfort Default AD forms",
          "type": "OTHER"
        },
        {
          "name": "Life Extension Default AD forms",
          "type": "OTHER"
        },
        {
          "name": "Standard Default AD forms",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Corporal Michael J. Crescenz VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2013-03",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-30",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01817686"
    },
    {
      "nct_id": "NCT00964873",
      "title": "A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Blast-phase Chronic Myelogenous Leukemia",
        "AML",
        "ALL",
        "CML"
      ],
      "interventions": [
        {
          "name": "STA-9090 (ganetespib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synta Pharmaceuticals Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2009-08",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2014-09-18",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Baltimore, Maryland • Durham, North Carolina",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00964873"
    },
    {
      "nct_id": "NCT05162586",
      "title": "The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Enpatoran low dose",
          "type": "DRUG"
        },
        {
          "name": "Enpatoran medium dose",
          "type": "DRUG"
        },
        {
          "name": "Enpatoran high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 456,
      "start_date": "2022-03-31",
      "completion_date": "2024-11-20",
      "has_results": true,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 14,
      "location_summary": "Torrance, California • Brandon, Florida • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05162586"
    },
    {
      "nct_id": "NCT05188729",
      "title": "Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Basal Cell Carcinoma",
        "Skin Cancer",
        "Cancer of the Skin, Basal Cell",
        "Cancer of the Skin",
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "Part 1: VP-315 3 Day Dosing/Week",
          "type": "DRUG"
        },
        {
          "name": "Part 2: VP-315 3 Day Dosing/Week - Loading Dose",
          "type": "DRUG"
        },
        {
          "name": "Part 2: VP-315 3 Day Dosing/Week - No Loading Dose",
          "type": "DRUG"
        },
        {
          "name": "Part 2: VP-315 2 Day Dosing/Week - Split Dose",
          "type": "DRUG"
        },
        {
          "name": "Part 2: VP-315 3 Day Dosing/Week - Split Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verrica Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2022-02-01",
      "completion_date": "2024-04-15",
      "has_results": true,
      "last_update_posted_date": "2025-06-18",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 13,
      "location_summary": "San Diego, California • Boca Raton, Florida • Coral Springs, Florida + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Saint Augustine",
          "state": "Florida"
        },
        {
          "city": "Snellville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05188729"
    },
    {
      "nct_id": "NCT05935631",
      "title": "Feasibility, Acceptability and Directional Signal Effect on Blood Folate Levels of Iodized Salt Fortified With Folic Acid: Clinical Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neural Tube Defects",
        "Folic Acid Deficiency",
        "Fortification"
      ],
      "interventions": [
        {
          "name": "Salt with folic acid and iodine",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2023-01-24",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05935631"
    },
    {
      "nct_id": "NCT04455620",
      "title": "BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BNT151",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2021-01-26",
      "completion_date": "2024-05-28",
      "has_results": true,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-11-11T10:38:18.216Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Nashville, Tennessee • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04455620"
    }
  ]
}